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  EVIDENCE-BASED ANSWER 
The international normalized ratio (INR) should be measured monthly once therapeutic levels are achieved and 
are stable for at least 8 weeks, although treatment should be individualized and an increased frequency may 
be required by some patients (Table) (strength of recommendation [SOR]: C, consensus statements). For 
highly compliant patients with stable levels and a clear understanding of factors that influence anticoagulation 
(changes in health, diet, medications), routine monitoring may be extended to 6 weeks (SOR: B, single 
randomized controlled trial [RCT]) or longer (SOR: C, case series). Patient-managed warfarin therapy, using 
biweekly self-measurements, results in more time in therapeutic range than routine physicianmanaged care 
(SOR: A, RCTs). 
 
TABLE 
Approach to monitoring of INR for long-term anticoagulation 
Clinical scenario Suggested approach 
Initiation of warfarin Monitor daily until stable, then gradually increase interval 
to weekly, biweekly, monthly if stable 
INR reaches 
therapeutic level 
Recheck 2 weeks x 2, then every 4 weeks if stable 
INR therapeutic for 
8 to 10 weeks 
consecutively 
May increase interval to 6 weeks with high compliance 
and good patient education; increase frequency with 
illness, medication change, history of highly variable INR 
levels 
INR outside target Recheck in 1 to 2 weeks; if persists, adjust dose and 
range within 1.0 
points 
recheck in 1–2 weeks 
INR > from target 
range but less than 
5 
Adjust dose, recheck in 1 week 
INR between 5 and 
8.9 
Hold warfarin 1 to 2 days, recheck 24 to 48 hours, adjust 
dose, consider oral vitamin K, but may lead to warfarin 
resistance 
INR >9 Hold warfarin, closely monitor. Bleeding risk increases 
with higher INR levels. Management may include 
admission, administration of oral or IV vitamin K, 
transfusion with fresh frozen plasma if INR very high or 
high risk of bleeding 
  EVIDENCE SUMMARY 
Under- or over-treatment with warfarin can result in life-threatening complications. Limited research exists to 
guide the selection of an interval for monitoring anticoagulation in stabilized patients. One RCT compared INR 
monitoring in an anticoagulation clinic at 6 weeks and 4 weeks among 124 patients with a prosthetic heart 
valve on stable oral anticoagulant treatment and found no difference in thromboembolic or hemorrhagic 
events.1 A study in the United Kingdom used a 14-week interval for selected patients, but it used no 
comparison group.2 Kent et al developed a computer-based model to compute the optimum interval for 
monitoring anticoagulation that considers the variability of the patient’s previous levels and costs associated 
with testing and potential complications. This model achieved a maximum interval of 11 weeks for very stable 
patients.3 
More frequent testing results in higher time in therapeutic range, particularly when patients selfmonitor. A 
German study of 200 patients with prosthetic heart valves found that they tested within a therapeutic range 
48% of the time when monitored by their physician “as usual” (average interval 24 days), and 64% of the time 
when the interval was increased to 2 weeks.4 When the same patients then went to self-monitoring every 8, 4, 
and 2 days, they achieved therapeutic levels 76%, 89%, and 90% of the time, respectively. Bleeding and 
thromboembolic complications were not reported, but have been demonstrated elsewhere to be lower among 
patients who self-test frequently (eg, twice weekly) when compared with usual care (average interval 19 days) 
(4.49% and 0.9% vs 10.9% and 3.6%; number needed to treat [NNT]=15.6 for bleeding, NNT=37 for 
thromboembolism).5 
  RECOMMENDATIONS FROM OTHERS 
The American College of Chest Physicians (ACCP) recommends individualizing management as the optimal 
frequency of INR monitoring varies according to patient compliance, dosing decisions, duration of therapy and 
changes in health, diet, or medications.6 The ACCP, the American Heart Association,7 Micromedex DrugPoints 
System,8 Goodman and Gilman’s Pharmacological Basis of Therapeutics.,9 and Cecil’s Textbook of 
Medicine.10 all recommend monthly monitoring once stable. The Institute for Clinical Systems Improvement’s 
Anticoagulation Therapy Supplement Management.11 and Managing Oral Anticoagulation Therapy Clinical and 
Operation al Guidelines.12 also recommend monthly monitoring for stable patients, but suggest that the interval 
can be increased to 6 weeks for selected stable patients. 
CLINICAL COMMENTARY 
Clear and consistent communication between 
physician and patient is essential 
 
Rick  Guthmann,  MD 
Advocate Illinois Masonic Medical Center 
Once a month warfarin monitoring remains a sensible interval after the therapeutic level is 
achieved. Maintaining a standard routine simplifies the many instructions that physicians 
give and patients receive. This clear, consistent plan can improve coordination of care by 
medical staff and compliance by patients. Additionally, monitoring has secondary benefits; 
it reinforces the risks associated with warfarin, and it provides further opportunities to 
educate the patient. 
MLIS, Medical College of Wisconsin, Milwaukee 
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